食道内視鏡的粘膜下層剥離術に関する多施設前向きコホート (FEO)
前向き多施設コホート研究:食道内視鏡的粘膜下層剥離術における技術的、腫瘍学的、組織的アウトカムの実臨床評価
In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.
Surgery was historically the standard treatment for localized disease but carries significant morbidity. Over the past decade, endoscopic treatments, particularly endoscopic submucosal dissection (ESD), have become the reference approach for superficial esophageal cancers.
After endoscopic resection, histological analysis allows classification of recurrence risk into very low, low, and high categories. Predicting lymph node or distant recurrence is complex, depending on factors such as depth of wall infiltration, lymphovascular invasion, and tumor differentiation. The frequent combination of unfavorable histological features may have led to an overestimation of lymph node involvement risk in T1b cancers.
ESD is widely performed in France, with over 1,600 procedures reported in 2023 for esophageal and gastric lesions, demonstrating the feasibility of a large observational study.
This multicenter French cohort will evaluate technical, oncological, and organizational outcomes of esophageal ESD, including overall survival, recurrence-free survival, and management of residual Barrett's esophagus. It will also identify predictive factors for treatment success, recurrence, and complications, providing real-world evidence to guide patient management.
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
連絡先と場所
研究連絡先
研究連絡先
- 名前:Bertrand BB BRIEAU, MD
- 電話番号:+33 +33650266383
- メール:bertrand.brieau@gmail.com
研究連絡先のバックアップ
- 名前:Maira MORENO, PhD
- 電話番号:+33(0)472117513
- メール:rechercheclinique@sfed.org
研究場所
-
-
-
Bordeaux、フランス
- 募集
- CHU de Bordeaux - Hôpital Haut-Lévêque
-
Limoges、フランス
- 募集
- CHU de Limoges - Hôpital Dupuytren 1
-
Lyon、フランス
- 募集
- Hôpital Édouard Herriot
-
Nancy、フランス
- 募集
- CHRU de Nancy - Hôpital Brabois
-
Nantes、フランス、44300
- 募集
- Jules Verne Clinic
-
コンタクト:
- Bertrand BRIEAU
- 電話番号:0033650266383
- メール:bertrand.brieau@gmail.com
-
Rennes、フランス
- 募集
- CHU de Rennes - Hôpital Pontchaillou
-
Rouen、フランス
- 募集
- Clinique Saint-Hilaire
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
Eligible patients include all individuals referred to a participating center for endoscopic resection of an esophageal lesion and treated by submucosal dissection. This is a prospective, multicenter, observational study, conducted on an intention-to-treat basis. All consecutive patients referred for esophageal ESD will be included.
説明
Inclusion Criteria:
- Adults (≥ 18 years old)
- Patients referred for endoscopic resection of an esophageal lesion and treated by submucosal dissection
- Patients managed in one of the participating centers
- Patient who has received oral and written information about the study and has not objected to participation
- Patients covered by a social security or health insurance scheme.
Exclusion Criteria:
- Patient refusal after reading the information sheet
- Patient under legal protection (guardianship, curatorship, court-ordered protection)
- Inability to inform the patient due to cognitive impairment, language barrier, or medical emergency
- Patients previously included for another lesion in the same study
- Pregnant or breastfeeding women.
- Patient deprived of liberty.
- Patient currently enrolled in another clinical trial.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:COHORT
- 時間の展望:PROSPECTIVE
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Recurrence-free survival according to adjuvant treatment
時間枠:From enrollment to 5 years
|
Recurrence-free survival will be evaluated in patients after endoscopic submucosal dissection (ESD) of superficial esophageal carcinoma. Patients may receive adjuvant therapy (surgery, chemotherapy, or chemoradiotherapy) at the treating physician's discretion. Recurrence includes local, regional, or metastatic relapse as defined by clinical, endoscopic, and imaging criteria and validated by multidisciplinary team discussion. Recurrence will be monitored throughout the 5-year follow-up period to compare outcomes between patients receiving adjuvant therapy versus surveillance. |
From enrollment to 5 years
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
R0 resection rate
時間枠:From ESD to 5 years
|
Proportion of patients with tumor-free lateral and deep margins confirmed by histopathology. |
From ESD to 5 years
|
|
En bloc resection rate
時間枠:From ESD to 5 years
|
Proportion of lesions resected in a single piece exclusively by ESD. |
From ESD to 5 years
|
|
Curative resection rate
時間枠:From ESD to 5 years
|
Proportion of R0 resections meeting favorable histological criteria: no lymphovascular invasion, no tumor budding, well-differentiated tumor, submucosal invasion <200 µm (squamous cell carcinoma) or <500 µm (adenocarcinoma). |
From ESD to 5 years
|
|
30-day complication rate
時間枠:30 days post-ESD
|
Rate of per- or post-procedural bleeding, immediate or delayed perforation, and strictures requiring endoscopic dilation. |
30 days post-ESD
|
|
Rate of MDTB presentation
時間枠:From ESD to 5 years
|
Proportion of patients whose management was discussed in a multidisciplinary team meeting. |
From ESD to 5 years
|
|
Concordance between MDTB decision and actual management
時間枠:From ESD to 5 years
|
Proportion of patients for whom the implemented management matched the MDTB recommendation. |
From ESD to 5 years
|
|
Rate of patients receiving adjuvant treatment
時間枠:From enrollment to 5 years
|
Proportion of patients receiving any adjuvant therapy after ESD (surgery, radiotherapy, chemotherapy, immunotherapy, etc.). |
From enrollment to 5 years
|
|
Rate of complementary Barrett's eradication treatment (radiofrequency or other)
時間枠:From ESD to 5 years
|
Proportion of patients treated for residual Barrett's esophagus using radiofrequency ablation or other endoscopic techniques. |
From ESD to 5 years
|
|
Morbidity of complementary treatments
時間枠:From ESD to 5 years
|
Rate of complications related to adjuvant therapy or Barrett's treatment |
From ESD to 5 years
|
|
Efficacy of complementary treatments
時間枠:From complementary treatment to 5 years
|
Rate of complete remission of intestinal metaplasia or oncologic control following complementary tratmets |
From complementary treatment to 5 years
|
|
Prognostic factors for recurrence (local, regional, metastatic)
時間枠:From enrollment to 5 years
|
Identification of clinical, endoscopic, and histological variables associated with increased risk of recurrence, analyzed using univariate and multivariate methods. |
From enrollment to 5 years
|
|
Predictive factors for post-ESD complications
時間枠:From ESD to 5 years
|
Analysis of factors associated with immediate or delayed complications (bleeding, perforation, stenosis) according to patient characteristics, ESD procedure, and adjuvant therapy. |
From ESD to 5 years
|
|
Predictive factors for R0 resection
時間枠:From ESD to 5 years
|
Analysis of clinical, endoscopic, and procedural variables predictive of complete R0 resection. |
From ESD to 5 years
|
|
Diagnostic accuracy of optical endoscopic classifications vs. histology
時間枠:From ESD to pathology report
|
Accuracy of endoscopic optical classifications in predicting histology prior to resection, compared to histopathology results. |
From ESD to pathology report
|
|
Impact of center volume on outcomes
時間枠:From enrollment to 5 years
|
Evaluation of the influence of annual ESD procedure volume in a center on technical and oncologic outcomes |
From enrollment to 5 years
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- SFED-162
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。